Skip to content

Halozyme Therapeutics HALO Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin82.8%-0.7pp83.6%-0.7pp84.5%+2.5pp84.2%+4.2pp83.4%+4.9pp
Efficiency
Asset turnover0.6×+0.1×0.6×+0.1×0.6×+0.1×0.6×+0.1×0.5×0.0×
Liquidity
Current ratio2.8×-5.6×4.7×-3.1×1.6×-8.8×8.4×+1.0×8.4×+1.8×
Leverage
Debt-to-equity9.9×+6.7×44.6×+40.4×3.1×-0.3×4.6×-0.7×3.2×-5.4×
Per Share
Book value per share$1.79-53.1%$0.39-86.0%$4.12+18.4%$2.68+19.7%$3.81+176%
Valuation
Market capitalization$7.66B-2.9%$7.91B+30.1%$8.58B+17.9%$6.64B-0.1%$7.88B+52.6%
Price / sales5.1×-2.2×5.7×-0.3×6.9×-0.8×5.6×-2.0×7.3×+1.3×
Price / book34.9×+18.5×162.1×+145×17×+1.0×20×-3.0×16.3×-12.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Halozyme Therapeutics's profit margins?
Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.
Where do Halozyme Therapeutics's ratios come from?
Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.